More than 15 new obesity medications are expected to gain approval over the next five years
BRAF(E600) in benign and malignant human tumours
Coverage for GLP-1 weight loss treatment is decreasing, Trent adds, due to stricter eligibility, caps, and prior authorization requirements. Beyond cost According to Trent, [Employers are] asking questions like, How many employees are likely to use it
* Correspondence: Vanessa Castelli, [email protected] These authors share first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
They are often more accessible than traditional primary care offices and can handle a variety of medical issues, including minor injuries and illnesses